{"id":783735,"date":"2023-09-13T09:03:57","date_gmt":"2023-09-13T13:03:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/"},"modified":"2023-09-13T09:03:57","modified_gmt":"2023-09-13T13:03:57","slug":"aspira-womens-health-regains-nasdaq-compliance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/","title":{"rendered":"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">AUSTIN, Texas, Sept.  13, 2023  (GLOBE NEWSWIRE) &#8212; Aspira\u00a0Women\u2019s Health Inc. (\u201cAspira\u201d\u00a0or \u201cthe Company\u201d)\u00a0(Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women\u2019s health diagnostic tools for gynecologic diseases, today\u00a0announced\u00a0that it received written notice from the Nasdaq Stock Market LLC (\u201cNASDAQ\u201d) on September 12, 2023 informing the Company that it has regained compliance with the market value of listed securities (\u201cMVLS\u201d) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the \u201cRule\u201d) for continued listing on the Nasdaq Capital Market.<\/p>\n<p>\n        <strong>About\u00a0Aspira\u00a0Women\u2019s\u00a0Health\u00a0Inc.\u00a0<\/strong><br \/>\n        <br \/>Aspira Women\u2019s Health Inc. is transforming women\u2019s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.\u00a0\u00a0\u00a0<\/p>\n<p>Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite<sup>SM<\/sup>, which includes OvaWatch<sup>SM<\/sup>, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus<sup>\u00ae<\/sup>\u00a0combines our FDA-cleared products, Ova1<sup>\u00ae\u00a0<\/sup>and Overa<sup>\u00ae<\/sup>, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.\u00a0\u00a0\u00a0<\/p>\n<p>EndoCheck<sup>SM<\/sup>, Aspira\u2019s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y5WcCR5Rt4i-d0POeGlxCMVD9DSGcOSTIkVZYUQ6IIKrosgubE6CUqNc1q6vdBOiqa4syOmAFWztL8xZd6BG1X4RoqujLrqwKSvJLAD2Xsrmbz-74-C9bcrrWE2Yaue0PLnNw3aXAXWku3bv17aZ3ufXScaoS93rje85SSSUK5kQNFCs5pv_UM0PS4QMhF92F1QpyE3WYqO_K4qEAqr-CiOMLGJPTtCRSwuTEJQHuPe9ce6FoyYZP3GZoUyh-hXoP54502eeZtox04BfTzH4c9_7ykgfIuk6ySzq8qIjLyagLV20fLUlUyYGlsjH_ZXMicRg0T_hjafXF4eCtzOVGdV4PtBllYkaBXUvJnKNZs2BFHdx4nWItat2bvlKgOMxwoWRNWMN75sIOGkRKvYOU9stJc4EDO8XuX_s_xwG875705IsRbXTw52ftoDltUpmd20PVxFkDTJG_cihJejrXAMBVwZf4PZKaqMUMOfLvu4P5h6H7Tt12qswn4BKS0ZuCpusZvqvg1bwPnUx6SZP6Lk138HBobe26EyXDlhiMd308e95SiKjxpUozchL5TBZj09g7K6x_lQUVAmwFHkTVM990DY6BTMntKuiizVgNB5zTeEHeenFoaeJyOQ31ikAQqOSA4NxpE5GSTY2yDF7gtLTL3zvIEdAKRZRSjp-gO8=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.aspirawh.com<\/u><\/a>.\u00a0\u00a0<\/p>\n<p>\n        <strong>Forward-Looking<\/strong>\u00a0<strong>Statements<\/strong><br \/>This\u00a0press\u00a0release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995.\u00a0All statements, other than statements of present or historical fact included in this press release are forward-looking statements.\u00a0Forward-looking statements involve\u00a0a number of\u00a0risks and uncertainties. Words such as \u201cmay,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cplans,\u201d \u201cseeks,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d \u201cwill,\u201d \u201cpotential,\u201d \u201cprojects\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to\u00a0a number of\u00a0risks, uncertainties, and assumptions, including those described in the section entitled \u201cRisk Factors\u201d in Aspira\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, and as supplemented in Aspira\u2019s 10-Q filings\u00a0for the quarter ended March 31,\u00a02023\u00a0and June 30, 2023. These risks include, but are not limited to: our ability to continue as a going concern; our ability to maintain Nasdaq\u2019s continued listing requirements; impacts resulting from potential changes to coverage of Ova1 through our Medicare Administrative Carrier for Ova1; anticipated use of capital and its effects; our ability to increase the volume of our product sales; failures by third-party payers to reimburse for our products and services or changes to reimbursement rates; our ability to continue developing existing technologies and to develop, protect and promote our proprietary technologies; plans to develop and perform laboratory developed tests; our ability to comply with Food and Drug Administration (\u201cFDA\u201d) regulations that relate to our products and to obtain any FDA clearance or approval required to develop and commercialize medical devices; our ability to develop and commercialize additional diagnostic products and achieve market acceptance with respect to these products; our ability to compete successfully; our ability to obtain any regulatory approval required for our future diagnostic products; or our suppliers\u2019 ability to comply with FDA requirements for production, marketing and post-market monitoring of our products; our ability to maintain sufficient or acceptable supplies of immunoassay kits from our suppliers; in the event that we succeed in commercializing our products outside the United States, the political, economic and other conditions affecting other countries; changes in healthcare policy; our ability to comply with the additional laws and regulations that apply to us in connection with the operation of Aspira Labs; our ability to use our net operating loss carryforwards; our ability to use intellectual property; our ability to successfully defend our proprietary technology against third parties; our ability to obtain licenses in the event a third party successfully asserts proprietary rights; the liquidity and trading volume of our common stock; the concentration of ownership of our common stock; our ability to retain key employees; our ability to secure additional capital on acceptable terms to execute our business plan; business interruptions; the effectiveness and availability of our information systems; our ability to integrate and achieve anticipated results from any acquisitions or strategic alliances; future litigation against us, including infringement of intellectual property and product liability exposure; and additional costs that may be required to make further improvements to our laboratory operations. The events and circumstances reflected in Aspira\u2019s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Aspira expressly\u00a0disclaims\u00a0any obligation to update, amend or clarify any forward-looking statements whether\u00a0as a result of\u00a0new information, future events or otherwise, except as required by law.<\/p>\n<p>\n        <strong><br \/>\n          <em>Investor Relations Contact:<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Monique Kosse\u00a0<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/>Tel: 212-915-3820<br \/><strong><em><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IaQ0aPayAn0kNEdnJdI9QUr0gxyHxnu23fOr210n5EgbsCv6847A4zDTVdo_4W8FkkCcp6dyohZ-_EbnWnewAfknwPOIEL54sr5FMNhEWedlmyw2we-YZBmRoWGXOUDo\" rel=\"nofollow noopener\" target=\"_blank\">monique@lifesciadvisors.com<\/a><\/u><\/em><\/strong><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzdlMDJjMGYtNTE0ZS00M2FiLTkyNmUtNTg4YzQwNDgxZGI4LTUwMDA0NTYzNw==\/tiny\/Aspira-Women-s-Health-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) &#8212; Aspira\u00a0Women\u2019s Health Inc. (\u201cAspira\u201d\u00a0or \u201cthe Company\u201d)\u00a0(Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women\u2019s health diagnostic tools for gynecologic diseases, today\u00a0announced\u00a0that it received written notice from the Nasdaq Stock Market LLC (\u201cNASDAQ\u201d) on September 12, 2023 informing the Company that it has regained compliance with the market value of listed securities (\u201cMVLS\u201d) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the \u201cRule\u201d) for continued listing on the Nasdaq Capital Market. About\u00a0Aspira\u00a0Women\u2019s\u00a0Health\u00a0Inc.\u00a0 Aspira Women\u2019s Health Inc. is transforming women\u2019s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.\u00a0\u00a0\u00a0 Our ovarian cancer risk assessment portfolio &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-783735","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) &#8212; Aspira\u00a0Women\u2019s Health Inc. (\u201cAspira\u201d\u00a0or \u201cthe Company\u201d)\u00a0(Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women\u2019s health diagnostic tools for gynecologic diseases, today\u00a0announced\u00a0that it received written notice from the Nasdaq Stock Market LLC (\u201cNASDAQ\u201d) on September 12, 2023 informing the Company that it has regained compliance with the market value of listed securities (\u201cMVLS\u201d) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the \u201cRule\u201d) for continued listing on the Nasdaq Capital Market. About\u00a0Aspira\u00a0Women\u2019s\u00a0Health\u00a0Inc.\u00a0 Aspira Women\u2019s Health Inc. is transforming women\u2019s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.\u00a0\u00a0\u00a0 Our ovarian cancer risk assessment portfolio &hellip; Continue reading &quot;Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-13T13:03:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance\",\"datePublished\":\"2023-09-13T13:03:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/\"},\"wordCount\":838,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/\",\"name\":\"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==\",\"datePublished\":\"2023-09-13T13:03:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-regains-nasdaq-compliance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/","og_locale":"en_US","og_type":"article","og_title":"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance - Market Newsdesk","og_description":"AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) &#8212; Aspira\u00a0Women\u2019s Health Inc. (\u201cAspira\u201d\u00a0or \u201cthe Company\u201d)\u00a0(Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women\u2019s health diagnostic tools for gynecologic diseases, today\u00a0announced\u00a0that it received written notice from the Nasdaq Stock Market LLC (\u201cNASDAQ\u201d) on September 12, 2023 informing the Company that it has regained compliance with the market value of listed securities (\u201cMVLS\u201d) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the \u201cRule\u201d) for continued listing on the Nasdaq Capital Market. About\u00a0Aspira\u00a0Women\u2019s\u00a0Health\u00a0Inc.\u00a0 Aspira Women\u2019s Health Inc. is transforming women\u2019s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.\u00a0\u00a0\u00a0 Our ovarian cancer risk assessment portfolio &hellip; Continue reading \"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-13T13:03:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance","datePublished":"2023-09-13T13:03:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/"},"wordCount":838,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/","name":"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==","datePublished":"2023-09-13T13:03:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=783735"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783735\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=783735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=783735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=783735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}